Physician profile
Laura E Martin
NPI 1528351640
$13,150.26
in general payments reported to CMS, 2019-2025
27 companies · $550 in 2025
The $550 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,268 · 2020: $523 · 2021: $98.50 · 2022: $3,443 · 2023: $6,321 · 2024: $947 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,000 · Food and Beverage: $1,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,000.00 |
| Food and Beverage | $1,817.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,391.62 | 2022-2023 | Davinci Xi |
| Coloplast Corp | $1,581.36 | 2019-2025 | Altis |
| Caldera Medical, INC | $514.87 | 2019-2024 | Desara |
| C. R. Bard, INC. & Subsidiaries | $408.82 | 2019-2022 | |
| Medtronic, INC. | $299.05 | 2022-2024 | Interstim |
| Medtronic USA, INC. | $295.24 | 2019-2020 | |
| Axonics, INC. | $259.26 | 2022-2024 | Axonics |
| Astellas Pharma US INC | $240.95 | 2022-2025 | Veozah, Myrbetriq |
| Rochester Medical Corporation | $170.23 | 2019-2020 | |
| Abbvie INC. | $156.27 | 2024-2025 | |
| Galderma Laboratories, L.P. | $150.25 | 2024 | |
| Urovant Sciences INC | $93.04 | 2022 | |
| Janssen Biotech, INC. | $85.22 | 2019-2025 | Erleada |
| Bard Access Systems, INC. | $70.36 | 2019 | |
| Evofem Biosciences, INC. | $62.23 | 2024-2025 | Solosec, Phexx, Phexxi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $57.80 | 2024-2025 | Aptima |
| Sumitomo Pharma America, INC. | $45.13 | 2024-2025 | Gemtesa, Myfembree |
| Integra Lifesciences Corporation | $43.00 | 2025 | Integra, Omnigraft, Surgimend |
| Escala Medical INC. | $34.94 | 2024 | |
| Bluewind Medical | $31.07 | 2025 | Revi |
| Applied Medical Resources Corporation | $27.80 | 2022 | |
| 180 Medical, INC. | $24.29 | 2025 | |
| Kerecis Limited | $22.76 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Millicent US INC | $22.31 | 2024 | Femring, Intrarosa |
| Merck Sharp & Dohme LLC | $22.06 | 2025 | Bridion |
| Laborie Medical Technologies Corp. | $21.39 | 2024 | Eclipse |
| Pfizer INC. | $18.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.